NCT00049842View on ClinicalTrials.gov

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

540

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Chronic Hepatitis CLiver Fibrosis

Interventions

BIOLOGICAL

peginterferon alfa-2b (SCH 54031)

0.5 µg/kg Weekly QW SC for 36 months

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00049842 - Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) | Biotech Hunter | Biotech Hunter